Article Text

This article has a correction. Please see:

Download PDFPDF
Beneficial response to rituximab in a patient with haemolysis and refractory Felty syndrome
  1. A Salama1,
  2. U Schneider2,
  3. T Dörner1,3
  1. 1
    Department of Transfusion Medicine and Immune Hematology
  2. 2
    Department of Medicine, Rheumatology and Clinical Immunology, Charite Universitätsmedizin Berlin, Germany
  3. 3
    Deutsches Rheumaforschungszentrum, Berlin, Germany
  1. Thomas Dörner, Charite Universitätsmedizin Berlin, Chariteplatz 1, 10098 Berlin, Germany; thomas.doerner{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Felty syndrome is characterised by chronic arthritis, splenomegaly and leucopenia. Although anaemia is present in many affected patients, significant haemolysis has not yet been described. While disease-modifying agents do not seem to improve leucopenia and anaemia, splenectomy results in a prompt relief of the haematological manifestations in most cases.13 To date, rituximab has been used in the treatment of three patients with Felty syndrome, and the haematological manifestation was improved in one patient only.4 5

We report on an improvement of both arthritis and haemolysis, but not of neutropenia and thrombocytopenia, …

View Full Text


  • Competing interests: None.

Linked Articles

  • Correction
    BMJ Publishing Group Ltd and European League Against Rheumatism